Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2942-2952

  Richard, Mathilde ^a   Ferraris, Olivier ^a   Erny, Alexandra ^a   Barthélémy, Mendy ^a   Traversier, Aurélien ^a   Sabatier, Murielle ^a   Hay, Alan ^b   Lin, Yi Pu ^b   Russell, Rupert J ^c   Lina, Bruno ^a  

^a UNIVERSITÉ DE LYON   (France)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

ANIMAL CELL; ANTIVIRAL RESISTANCE; ARTICLE; CELL STRAIN; CLOSTRIDIUM PERFRINGENS; COMBINATORIAL CHEMISTRY; COMPETITIVE INHIBITION; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENETIC COMPLEMENTATION; IC 50; INFLUENZA VIRUS A H3N2; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; VIRAL GENETICS; VIRION; VIROGENESIS; VIRUS REPLICATION; WILD TYPE;

ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; CELLS, CULTURED; DOGS; DRUG RESISTANCE, VIRAL; INFLUENZA A VIRUS, H3N2 SUBTYPE; MUTATION; NEURAMINIDASE; OSELTAMIVIR; VIRION;

EID: 79956307892     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01699-10     Document Type: Article

References (66)

1. Abed, Y., M. Baz, and G. Boivin. 2006. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 11:971-976.
2. Abed, Y., N. Goyette, and G. Boivin. 2004. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther. 9:577-581.
3. Abed, Y., B. Nehme, M. Baz, and G. Boivin. 2008. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Res. 77:163-166.
4. Anonymous. 2009. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:969-972.
5. Baker, A. T., J. N. Varghese, W. G. Laver, G. M. Air, and P. M. Colman. 1987. Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins 2:111-117.
6. Baranovich, T., et al. 2010. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. J. Clin. Virol. 47:23-28.
7. Baz, M., Y. Abed, and G. Boivin. 2007. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res. 74:159-162. (Pubitemid 46436166)
8. Baz, M., Y. Abed, J. McDonald, and G. Boivin. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin. Infect. Dis. 43:1555-1561.
9. Baz, M., Y. Abed, P. Simon, M. E. Hamelin, and G. Boivin. 2010. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J. Infect. Dis. 201:740-745.
10. Bloom, J. D., L. I. Gong, and D. Baltimore. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328:1272-1275.
11. Bouvier, N. M., A. C. Lowen, and P. Palese. 2008. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J. Virol. 82:10052-10058.
12. Carr, J., et al. 2002. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 54:79-88. (Pubitemid 34327686)
13. Casalegno, J. S., et al. 2010. Oseltamivir-resistant influenza A(H1N1) viruses in south of France, 2007/2009. Antiviral Res. [Epub ahead of print.] doi: 10.1016/j.antiviral.2010.05.010.
14. Chong, A. K., M. S. Pegg, N. R. Taylor, and M. von Itzstein. 1992. Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus. Eur. J. Biochem. 207:335-343.
15. Colman, P. M., P. A. Hoyne, and M. C. Lawrence. 1993. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 67:2972-2980.
16. Colman, P. M., J. N. Varghese, and W. G. Laver. 1983. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41-44.
17. Dharan, N. J., et al. 2009. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301:1034-1041.
18. Escuret, V., et al. 2008. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J. Clin. Virol. 41:25-28.
19. Ferraris, O., N. Kessler, and B. Lina. 2005. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res. 68:43-48. (Pubitemid 41338581)
20. Ferraris, O., and B. Lina. 2008. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol. 41:13-19.
21. Gubareva, L. V. 2004. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103:199-203.
22. Gubareva, L. V., et al. 1996. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. 70:1818-1827. (Pubitemid 26062945)
23. Gubareva, L. V., L. Kaiser, M. N. Matrosovich, Y. Soo-Hoo, and F. G. Hayden. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183:523-531.
24. Gubareva, L. V., M. J. Robinson, R. C. Bethell, and R. G. Webster. 1997. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71:3385-3390.
25. Hatakeyama, S., et al. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-1442. (Pubitemid 46556469)
26. Herlocher, M. L., et al. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54:99-111. (Pubitemid 34327688)
27. Herlocher, M. L., et al. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190:1627-1630.
28. Hoffmann, E., G. Neumann, Y. Kawaoka, G. Hobom, and R. G. Webster. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U. S. A. 97:6108-6113.
29. Hurt, A. C., I. G. Barr, G. Hartel, and A. W. Hampson. 2004. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res. 62:37-45.
30. Hurt, A. C., et al. 2009. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83:90-93.
31. Hurt, A. C., J. K. Holien, and I. G. Barr. 2009. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob. Agents Chemother. 53:4433-4440.
32. Jackson, D., W. Barclay, and T. Zurcher. 2005. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J. Antimicrob. Chemother. 55:162-169.
33. Kim, C. U., et al. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119:681-690.
34. Kiso, M., et al. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765. (Pubitemid 39165094)
35. Li, W., et al. 1998. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42:647-653.
36. Liu, C., M. C. Eichelberger, R. W. Compans, and G. M. Air. 1995. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J. Virol. 69:1099-1106.
37. Lowen, A. C., S. Mubareka, T. M. Tumpey, A. Garcia-Sastre, and P. Palese. 2006. The guinea pig as a transmission model for human influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 103:9988-9992.
38. Matrosovich, M., T. Matrosovich, J. Carr, N. A. Roberts, and H. D. Klenk. 2003. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77:8418-8425.
39. Meijer, A., et al. 2009. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15:552-560.
40. Mishin, V. P., F. G. Hayden, and L. V. Gubareva. 2005. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49:4515-4520.
41. Monto, A. S., et al. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50:2395-2402.
42. Moules, V., et al. 2010. In vitro characterization of naturally occurring influenza H3NA- viruses lacking the NA gene segment: toward a new mechanism of viral resistance? Virology 404:215-224.
43. Okomo-Adhiambo, M., et al. 2010. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob. Agents Chemother. 54:1834-1841.
44. Palese, P., and R. W. Compans. 1976. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J. Gen. Virol. 33:159-163.
45. Palese, P., K. Tobita, M. Ueda, and R. W. Compans. 1974. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61:397-410.
46. Rameix-Welti, M. A., et al. 2006. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob. Agents Chemother. 50:3809-3815.
47. Rameix-Welti, M. A., V. Enouf, F. Cuvelier, P. Jeannin, and S. van der Werf. 2008. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 4:e1000103.
48. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
49. Richard, M., et al. 2008. Impact of influenza A virus neuraminidase mutations on the stability, activity, and sensibility of the neuraminidase to neuraminidase inhibitors. J. Clin. Virol. 41:20-24.
50. Rudrawar, S., et al. 2010. Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat. Commun. 1:113.
51. Russell, R. J., et al. 2006. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:45-49. (Pubitemid 44344043)
52. Sauter, N. K., et al. 1989. Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study. Biochemistry 28:8388-8396. (Pubitemid 19269029)
53. Sheu, T. G., et al. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob. Agents Chemother. 52:3284-3292.
54. Tai, C. Y., et al. 1998. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42:3234-3241.
55. Tashiro, M., et al. 2009. Surveillance for neuraminidase-inhibitor- resistant influenza viruses in Japan, 1996-2007. Antivir. Ther. 14:751-761.
56. Taylor, N. R., and M. von Itzstein. 1994. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J. Med. Chem. 37:616-624.
57. Tulip, W. R., et al. 1991. Refined atomic structures of N9 subtype influenza virus neuraminidase and escape mutants. J. Mol. Biol. 221:487-497.
58. Varghese, J. N., and P. M. Colman. 1991. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution. J. Mol. Biol. 221:473-486.
59. Varghese, J. N., W. G. Laver, and P. M. Colman. 1983. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 303:35-40.
60. Varghese, J. N., J. L. McKimm-Breschkin, J. B. Caldwell, A. A. Kortt, and P. M. Colman. 1992. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327-332.
61. von Itzstein, M., et al. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423.
62. Wang, M. Z., C. Y. Tai, and D. B. Mendel. 2002. Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother. 46:3809-3816.
63. Wetherall, N. T., et al. 2003. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41:742-750.
64. Yen, H. L., et al. 2005. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49:4075-4084.
65. Yen, H. L., et al. 2006. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol. 80:8787-8795.
66. Yen, H. L., et al. 2007. Inefficient transmission of H5N1 influenza viruses in a ferret contact model. J. Virol. 81:6890-6898.